Intravenous Thrombolysis for Acute Ischemic Stroke in Patients Receiving Antiplatelet Therapy: A Systematic Review and Meta‐analysis of 19 Studies
Open Access
- 6 May 2016
- journal article
- review article
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 5 (5) , e003242
Abstract
Background: The safety and long‐term outcome of systemic thrombolysis in patients receiving antiplatelet medications remain subjects of great clinical significance. The objective of this meta‐analysis was to determine how prestroke antiplatelet therapy affects the risks and benefits of intravenous thrombolysis in patients with acute ischemic stroke. Methods and Results: A dual‐reviewer search was conducted in PubMed and EMBASE databases through November 2015, from which 19 studies involving a total of 108 588 patients with acute ischemic stroke were identified based on preset inclusion criteria. Information on study designs, patient characteristics, exposures, outcomes, and adjusting confounders was extracted, and estimates were combined by using random‐effects models. The pooled crude estimates suggested that taking long‐term antiplatelet medications was associated with higher odds of symptomatic intracranial hemorrhage (odds ratio [OR] 1.70, 95% CI 1.47–1.97) and death ( OR 1.46, 95% CI 1.22–1.75) and lower odds of favorable functional outcomes ( OR 0.86, 95% CI 0.80–0.93). However, the combined confounder‐adjusted results only confirmed a relatively weak positive association between prior antiplatelet therapy and symptomatic intracranial hemorrhage ( OR 1.21, 95% CI 1.02–1.44) and demonstrated no significant relationship between antiplatelet therapy and the other 2 outcomes (favorable outcome OR 1.09, 95% CI 0.96–1.24; death OR 1.02, 95% CI 0.98–1.07). Subgroup analyses revealed that the associations between prestroke antiplatelet therapy and outcomes were dependent on time and antiplatelet agents. Conclusions: Patients with acute ischemic stroke receiving long‐term antiplatelet medications were associated with greater risks of developing symptomatic intracranial hemorrhage after systemic thrombolysis. However, the overall independent association between prestroke antiplatelet therapy and unfavorable outcomes or mortality was insignificant.Keywords
This publication has 41 references indexed in Scilit:
- Guidelines for the Early Management of Patients With Acute Ischemic StrokeStroke, 2013
- Thrombolysis in Stroke Despite Contraindications or Warnings?Stroke, 2013
- Early administration of aspirin in patients treated with alteplase for acute ischaemic stroke: a randomised controlled trialThe Lancet, 2012
- The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroke trial [IST-3]): a randomised controlled trialThe Lancet, 2012
- Recombinant tissue plasminogen activator for acute ischaemic stroke: an updated systematic review and meta-analysisThe Lancet, 2012
- Combined anti-platelet therapy with aspirin and clopidogrel: Risk factor for thrombolysis-related intracerebral hemorrhage in acute ischemic stroke?Journal of the Neurological Sciences, 2009
- Factors Associated With Intracerebral Hemorrhage After Thrombolytic Therapy for Ischemic StrokeStroke, 2009
- Antiplatelet Therapy and the Risk of Intracranial Hemorrhage After Intravenous Tissue Plasminogen Activator Therapy for Acute Ischemic StrokeArchives of Neurology, 2008
- Markedly Reduced Apparent Blood Volume on Bolus Contrast Magnetic Resonance Imaging as a Predictor of Hemorrhage After Thrombolytic Therapy for Acute Ischemic StrokeStroke, 2005
- Quantifying heterogeneity in a meta‐analysisStatistics in Medicine, 2002